ArticleCancer2022

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

Alberto Alvarez-Larrán et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.